Evidence map›Paper›PMID 28988712›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2018

Antimicrobial Peptide Combined with BMP2-Modified Mesenchymal Stem Cells Promotes Calvarial Repair in an Osteolytic Model.

Zunpeng Liu, Xue Yuan, Min Liu, Gabriela Fernandes, Yejia Zhang, Shuting Yang, Ciprian N Ionita, Shuying Yang

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 60 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Cathelicidin LL37 Promotes Osteogenic DifferentiationFrontiers in bioengineering and biotechnology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Zunpeng LiuDepartment of Oral Biology, School of Dental Medicine, University of Buffalo, The State University of New York, Buffalo, NY, USA; Department of Orthopedics, Fourth Affiliated Hospital, China Medical University, Shenyang, China.
Xue YuanDepartment of Oral Biology, School of Dental Medicine, University of Buffalo, The State University of New York, Buffalo, NY, USA.
Min LiuDepartment of Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Gabriela FernandesDepartment of Oral Biology, School of Dental Medicine, University of Buffalo, The State University of New York, Buffalo, NY, USA.
Yejia ZhangDepartments of Physical Medicine and Rehabilitation, School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Translational Musculoskeletal Research Center (TMRC), Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA.
Shuting YangDepartment of Oral Biology, School of Dental Medicine, University of Buffalo, The State University of New York, Buffalo, NY, USA; Department of Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ciprian N IonitaDepartment of Biomedical Engineering, State University of New York at Buffalo, Buffalo, NY, USA; Toshiba Stroke and Vascular Research Center, State University of New York at Buffalo, Buffalo, NY, USA.
Shuying YangDepartment of Oral Biology, School of Dental Medicine, University of Buffalo, The State University of New York, Buffalo, NY, USA; Department of Anatomy and Cell Biology, School of Dental Medicine, University of Pennsylvania, Philadelphia, PA, USA. Electronic address: shuyingy@upenn.edu.
University at Buffalo, State University of New York · USUniversity of Pennsylvania · USFourth Affiliated Hospital of China Medical University · CN

Funding

Regulation of skeletal development and homeostasis by IFT proteinR01DE023105 · NIDCR · UNIVERSITY OF PENNSYLVANIA · PI YANG, SHUYING · 2014 to 2018
$2.0M
Role of RGS12, a Regulator of G protein Signaling, in Bone RemodelingR01AR066101 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI YANG, SHUYING · 2014 to 2018
$1.8M
Function of Regulator of G protein signaling in aging skeletonR01AG048388 · NIA · UNIVERSITY OF PENNSYLVANIA · PI YANG, SHUYING · 2014 to 2018
$1.7M
NIAMS NIH HHS R01 AR066101NIA NIH HHS R01 AG048388NIDCR NIH HHS R01 DE023105
6 · The paper itself

Abstract

Repair and regeneration of inflammation-induced bone loss remains a clinical challenge. LL37, an antimicrobial peptide, plays critical roles in cell migration, cytokine production, apoptosis, and angiogenesis. Migration of stem cells to the affected site and promotion of vascularization are essential for tissue engineering therapy, including bone regeneration. However, it is largely unknown whether LL37 affects mesenchymal stem cell (MSC) behavior and bone morphogenetic protein 2 (BMP2)-mediated bone repair during the bone pathologic remodeling process. By performing in vitro and in vivo studies with MSCs and a lipopolysaccharide (LPS)-induced mouse calvarial osteolytic bone defect model, we found that LL37 significantly promotes cell differentiation, migration, and proliferation in both unmodified MSCs and BMP2 gene-modified MSCs. Additionally, LL37 inhibited LPS-induced osteoclast formation and bacterial activity in vitro. Furthermore, the combination of LL37 and BMP2 markedly promoted MSC-mediated angiogenesis and bone repair and regeneration in LPS-induced osteolytic defects in mouse calvaria. These findings demonstrate for the first time that LL37 can be a potential candidate drug for promoting osteogenesis and for inhibiting bacterial growth and osteoclastogenesis, and that the combination of BMP2 and LL37 is ideal for MSC-mediated bone regeneration, especially for inflammation-induced bone loss.

Indexed as

Bone RegenerationAnimalsAntimicrobial Cationic PeptidesBiomarkersBone Morphogenetic Protein 2Cell DifferentiationCell MovementCell ProliferationLipopolysaccharidesMesenchymal Stem CellsMiceOsteoclastsOsteogenesisOsteolysisSkullAntimicrobial Cationic PeptidesBiomarkersBone Morphogenetic Protein 2Lipopolysaccharidesantimicrobial peptidebone lossbone regenerationbone repairinflammationLL37mesenchymal stem cellsosteolysis

Identifiers

PMID28988712
PMCPMC5762982
OpenAlexW2754057655

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.